More Positive Data As Decision Day Looms For AstraZeneca Lupus Drug
Anifrolumab Improves Skin Rash And Arthritis
Competition to GlaxoSmithKline’s Benlysta in the systemic lupus erythematosus space finally looks imminent with approval decisions on AstraZeneca's anifrolumab pending. The company has presented more data at EULAR to make its case for the first-in-class type I interferon inhibitor.
